LitCovid-sample-Enju  

PMC:7205724 / 17405-19470 JSONTXT 21 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T55819 0-3 CD denotes 4.2
T56180 5-16 JJ denotes Intravenous
T2182 17-32 NNS denotes immunoglobulins
T41175 33-34 -LRB- denotes (
T97867 34-38 NN denotes IVIG
T16816 38-39 -RRB- denotes )
T56020 41-46 CD denotes 4.2.1
T95212 48-58 NN denotes Hypothesis
T84611 58-59 -COLON- denotes :
T95417 60-64 NN denotes IVIG
T50853 65-73 VBZ denotes contains
T65863 74-75 DT denotes a
T68527 76-81 JJ denotes large
T83960 82-86 NN denotes pool
T57480 87-89 IN denotes of
T98962 90-95 JJ denotes human
T50450 96-106 NNS denotes antibodies
T12037 107-111 NN denotes IVIG
T52317 112-114 VBZ denotes is
T83276 115-117 DT denotes an
T47689 118-134 JJ denotes immunomodulatory
T32201 135-144 NN denotes treatment
T26744 145-154 RB denotes currently
T6595 155-161 JJ denotes useful
T61951 162-165 IN denotes for
T78252 166-167 DT denotes a
T96672 168-175 NN denotes variety
T75647 176-178 IN denotes of
T64366 179-184 JJ denotes human
T37666 185-193 NNS denotes diseases
T30663 194-198 WDT denotes that
T71611 199-204 VBP denotes share
T4369 205-207 DT denotes an
T95969 208-218 JJ denotes idiopathic
T35011 219-225 NN denotes origin
T94518 225-226 -COMMA- denotes ,
T34533 227-234 VBG denotes ranging
T57537 235-239 IN denotes from
T47481 240-250 JJ denotes autoimmune
T10634 251-260 NNS denotes disorders
T96539 261-263 TO denotes to
T18270 264-271 JJ denotes primary
T92790 272-280 NN denotes antibody
T91348 281-293 NNS denotes deficiencies
T23275 295-299 RB denotes Also
T97483 299-300 -COMMA- denotes ,
T12179 301-305 NNP denotes IVIG
T44219 306-309 VBZ denotes has
T10629 310-315 VBN denotes shown
T45168 316-325 JJ denotes promising
T67208 326-333 NNS denotes results
T77083 334-336 IN denotes in
T72909 337-341 NN denotes case
T84121 342-344 IN denotes of
T92712 345-351 JJ denotes severe
T79863 352-353 -LRB- denotes (
T66824 353-357 JJ denotes such
T43956 358-360 IN denotes as
T9832 361-367 NN denotes sepsis
T13628 367-368 -COMMA- denotes ,
T62406 369-379 NN denotes Parvovirus
T99835 380-383 NN denotes B19
T14835 384-393 NN denotes infection
T15497 393-394 -COMMA- denotes ,
T90831 395-399 NNP denotes West
T76795 400-404 NNP denotes Nile
T72325 405-410 NN denotes virus
T62294 411-423 NN denotes encephalitis
T79163 423-424 -COMMA- denotes ,
T42313 425-428 NN denotes HIV
T73958 428-429 -COMMA- denotes ,
T29310 430-441 NNP denotes Clostridium
T49447 442-451 JJ denotes difficile
T8038 452-462 NNS denotes infections
T10219 462-463 -COMMA- denotes ,
T3443 464-477 NN denotes Mycobacterium
T55185 478-483 NN denotes avium
T2677 483-484 -COMMA- denotes ,
T67405 485-498 NN denotes Mycobacterium
T65630 499-511 NN denotes tuberculosis
T60726 511-512 -COMMA- denotes ,
T52785 513-516 CC denotes and
T44446 517-525 NNP denotes Nocardia
T90848 526-536 NNS denotes infections
T80386 536-537 -RRB- denotes )
T6178 538-541 CC denotes and
T68317 542-551 JJ denotes recurrent
T17705 552-562 NNS denotes infections
T68999 563-565 IN denotes in
T18422 566-573 JJ denotes primary
T52471 574-584 NNS denotes antibodies
T62247 585-597 NNS denotes deficiencies
T55724 598-599 -LRB- denotes [
T27007 599-601 CD denotes 21
T97422 601-602 -RRB- denotes ]
T8813 604-608 JJS denotes Most
T48684 609-617 NNS denotes patients
T37814 618-625 VBP denotes develop
T41895 626-636 NNS denotes antibodies
T32237 637-644 IN denotes against
T55833 645-648 DT denotes the
T23466 649-651 NN denotes NP
T51386 652-655 CC denotes and
T97267 656-659 NN denotes RBD
T48238 660-662 IN denotes of
T17626 663-672 NN denotes 2019-nCoV
T87676 673-679 IN denotes during
T56543 680-683 DT denotes the
T74019 684-690 JJ denotes second
T36179 691-695 NN denotes week
T61939 696-701 IN denotes after
T53819 702-711 NN denotes infection
T47949 712-717 NN denotes onset
T10621 718-719 -LRB- denotes [
T31327 719-721 CD denotes 22
T53799 721-722 -RRB- denotes ]
T76985 724-732 NN denotes Analysis
T6758 733-735 IN denotes of
T88720 736-741 NN denotes serum
T73739 742-749 NNS denotes samples
T20072 750-759 VBD denotes collected
T30704 760-762 CD denotes 14
T66398 763-765 CC denotes or
T43796 766-770 JJR denotes more
T64515 771-775 NNS denotes days
T88119 776-781 IN denotes after
T33297 782-789 NN denotes symptom
T78997 790-795 NN denotes onset
T69102 796-804 VBD denotes revealed
T51393 805-814 NN denotes detection
T49412 815-817 IN denotes of
T86080 818-821 NN denotes IgG
T42365 822-825 CC denotes and
T24248 826-829 NN denotes IgM
T84785 830-840 NNS denotes antibodies
T33598 841-848 IN denotes against
T65176 849-851 NN denotes NP
T29543 852-854 IN denotes in
T67075 855-857 CD denotes 94
T4274 857-858 NN denotes %
T73088 859-862 CC denotes and
T74097 863-865 CD denotes 88
T71868 865-866 NN denotes %
T54079 867-870 CC denotes and
T73098 871-874 NN denotes RBD
T69539 875-877 IN denotes in
T87988 878-881 CD denotes 100
T78691 881-882 NN denotes %
T18580 883-886 CC denotes and
T46489 887-889 CD denotes 94
T64615 889-890 NN denotes %
T60810 891-896 IN denotes among
T38563 897-905 NNS denotes patients
T93829 906-910 IN denotes with
T24980 911-918 NN denotes COVID19
T89545 920-927 NNS denotes Studies
T44838 928-940 RB denotes consistently
T54246 941-945 VBP denotes show
T20581 946-950 IN denotes that
T54967 951-960 VBN denotes increased
T27422 961-975 NN denotes immunoglobulin
T48431 976-982 NNS denotes levels
T7060 983-992 VBP denotes accompany
T92743 993-996 DT denotes the
T24866 997-1007 NN denotes transition
T9522 1008-1012 IN denotes from
T69120 1013-1018 JJ denotes early
T81312 1019-1021 TO denotes to
T7048 1022-1026 JJ denotes late
T25388 1027-1033 NN denotes course
T44741 1034-1036 IN denotes of
T20679 1037-1044 NN denotes COVID19
T6735 1046-1048 PRP denotes It
T32751 1049-1054 VBZ denotes poses
T41840 1055-1058 DT denotes the
T21434 1059-1070 NN denotes possibility
T75450 1071-1075 IN denotes that
T55251 1076-1080 NN denotes IVIG
T48129 1081-1088 NN denotes therapy
T90120 1089-1094 MD denotes might
T91321 1095-1099 VB denotes help
T89890 1100-1102 TO denotes to
T64443 1103-1113 VB denotes accelerate
T5150 1114-1122 NN denotes recovery
T43666 1123-1127 IN denotes from
T85289 1128-1136 NN denotes COVID-19
T72940 1139-1144 CD denotes 4.2.2
T31699 1146-1155 NNP denotes Rationale
T6254 1155-1156 -COLON- denotes :
T80516 1157-1161 NN denotes IVIG
T69063 1162-1167 MD denotes might
T22631 1168-1172 VB denotes help
T88012 1173-1175 TO denotes to
T98862 1176-1183 VB denotes improve
T98671 1184-1187 DT denotes the
T20348 1188-1195 NN denotes outcome
T65200 1196-1198 IN denotes of
T90061 1199-1207 NNS denotes patients
T66297 1208-1212 IN denotes with
T53417 1213-1221 NN denotes COVID-19
T18993 1222-1225 DT denotes The
T21718 1226-1231 NN denotes study
T64168 1232-1233 -LRB- denotes [
T66430 1233-1235 CD denotes 23
T95152 1235-1236 -RRB- denotes ]
T31198 1237-1245 VBD denotes included
T55004 1246-1249 CD denotes ten
T65830 1250-1258 NNS denotes patients
T56952 1259-1263 IN denotes with
T98815 1264-1272 NN denotes COVID-19
T69048 1273-1276 WP denotes who
T75376 1277-1289 VBD denotes demonstrated
T59786 1290-1299 VBG denotes worsening
T24326 1300-1308 NNS denotes symptoms
T13700 1308-1309 -COMMA- denotes ,
T79561 1310-1314 FW denotes e.g.
T83448 1314-1315 -COMMA- denotes ,
T77014 1316-1325 VBD denotes decreased
T40148 1326-1336 NN denotes lymphocyte
T31095 1337-1342 NN denotes count
T13833 1343-1346 CC denotes and
T80531 1347-1356 VBD denotes decreased
T26060 1357-1366 NN denotes PaO2/FIO2
T3471 1367-1372 NN denotes ratio
T11859 1373-1376 CC denotes and
T6067 1377-1383 NN denotes oxygen
T65980 1384-1394 NN denotes saturation
T58632 1394-1395 -COMMA- denotes ,
T52543 1396-1405 VBG denotes following
T84435 1406-1415 NN denotes treatment
T44273 1416-1420 IN denotes with
T99668 1421-1422 DT denotes a
T65524 1423-1433 JJ denotes short-term
T66169 1434-1447 JJ denotes moderate-dose
T25963 1448-1462 NN denotes corticosteroid
T54040 1463-1464 -LRB- denotes (
T15835 1464-1482 NN denotes methylprednisolone
T75851 1483-1490 NN denotes 80 mg/d
T55858 1490-1491 -RRB- denotes )
T6426 1492-1496 CC denotes plus
T60445 1497-1511 NN denotes immunoglobulin
T91733 1512-1513 -LRB- denotes (
T10263 1513-1519 CD denotes 10 g/d
T89099 1519-1520 -RRB- denotes )
T32422 1522-1527 IN denotes After
T38661 1528-1537 VBG denotes switching
T47400 1538-1540 TO denotes to
T27854 1541-1544 DT denotes the
T88178 1545-1551 JJ denotes double
T22917 1552-1556 NN denotes dose
T27562 1557-1559 IN denotes of
T69861 1560-1569 NN denotes 1600 mg/d
T26688 1570-1588 NN denotes methylprednisolone
T91618 1589-1593 CC denotes plus
T63033 1594-1600 NN denotes 20 g/d
T82872 1601-1615 NN denotes immunoglobulin
T48110 1615-1616 -COMMA- denotes ,
T64285 1617-1620 DT denotes all
T67888 1621-1623 IN denotes of
T16788 1624-1627 DT denotes the
T67776 1628-1636 NNS denotes patients
T6163 1637-1645 VBN denotes improved
T27596 1646-1648 IN denotes in
T10929 1649-1652 DT denotes the
T87507 1653-1661 JJ denotes clinical
T10805 1661-1662 -COMMA- denotes ,
T49266 1663-1673 NN denotes laboratory
T95692 1673-1674 -COMMA- denotes ,
T51590 1675-1678 CC denotes and
T63732 1679-1691 JJ denotes paraclinical
T58895 1692-1700 NNS denotes outcomes
T85504 1702-1709 JJ denotes Passive
T86520 1710-1722 NN denotes immunization
T22143 1723-1731 VBZ denotes protects
T80547 1732-1739 IN denotes against
T21735 1740-1747 NN denotes disease
T15590 1747-1748 -COMMA- denotes ,
T4169 1749-1752 CC denotes and
T50400 1753-1755 IN denotes so
T4187 1756-1758 PRP denotes it
T38504 1759-1765 MD denotes should
T8453 1766-1768 VB denotes be
T27914 1769-1781 VBN denotes administered
T25991 1782-1784 RB denotes as
T54707 1785-1790 RB denotes early
T29802 1791-1793 IN denotes as
T24869 1794-1802 JJ denotes possible
T10896 1803-1807 WRB denotes when
T25638 1808-1811 DT denotes the
T29960 1812-1819 NN denotes patient
T20464 1820-1822 VBZ denotes is
T3036 1823-1832 VBN denotes diagnosed
T87261 1834-1841 NNS denotes Studies
T96660 1842-1846 VBP denotes show
T29990 1847-1851 IN denotes that
T81080 1852-1855 DT denotes the
T36950 1856-1861 JJ denotes viral
T53426 1862-1865 NN denotes RNA
T78293 1866-1868 IN denotes of
T18048 1869-1878 NN denotes 2019-nCoV
T93176 1879-1886 VBZ denotes reaches
T83675 1887-1890 PRP-DOLLAR- denotes its
T2594 1891-1895 NN denotes peak
T62926 1896-1902 IN denotes during
T35185 1903-1906 DT denotes the
T47524 1907-1912 JJ denotes first
T79772 1913-1917 NN denotes week
T85972 1918-1921 CC denotes and
T60597 1922-1926 RB denotes then
T18711 1927-1936 RB denotes gradually
T40522 1937-1946 VBZ denotes decreases
T67874 1947-1950 CC denotes and
T80013 1951-1955 IN denotes that
T48373 1956-1959 NN denotes IgG
T85015 1960-1963 CC denotes and
T48892 1964-1967 NN denotes IgM
T97802 1968-1973 VBP denotes begin
T54813 1974-1976 TO denotes to
T87582 1977-1981 VB denotes rise
T15243 1982-1986 IN denotes from
T79089 1987-1990 DT denotes the
T92830 1991-1995 JJ denotes 10th
T91091 1996-1999 NN denotes day
T75308 2000-2002 IN denotes so
T98992 2003-2007 IN denotes that
T91226 2008-2012 JJS denotes most
T66875 2013-2021 NNS denotes patients
T44373 2022-2026 VBP denotes have
T45012 2027-2037 JJ denotes anti-viral
T2304 2038-2048 NNS denotes antibodies
T90719 2049-2051 IN denotes by
T66178 2052-2055 DT denotes the
T38757 2056-2060 JJ denotes 14th
T73930 2061-2064 NN denotes day
R10059 T24866 T92743 arg1Of transition,the
R10340 T87582 T75308 arg1Of rise,so
R10355 T66875 T91226 arg1Of patients,most
R10701 T32201 T94518 arg1Of treatment,","
R10991 T86520 T22143 arg1Of immunization,protects
R11280 T7048 T69120 arg1Of late,early
R11593 T25388 T9522 arg2Of course,from
R11871 T83960 T65863 arg1Of pool,a
R11936 T20348 T98671 arg1Of outcome,the
R12367 T90848 T44446 arg1Of infections,Nocardia
R12726 T37666 T71611 arg1Of diseases,share
R13100 T41895 T37814 arg2Of antibodies,develop
R13275 T62294 T15497 arg2Of encephalitis,","
R13579 T5150 T43666 arg1Of recovery,from
R13811 T2304 T44373 arg2Of antibodies,have
R14407 T21718 T64168 arg1Of study,[
R14592 T4187 T8453 arg1Of it,be
R14909 T58895 T10929 arg1Of outcomes,the
R15007 T84785 T49412 arg2Of antibodies,of
R15150 T48431 T54967 arg2Of levels,increased
R15494 T87261 T96660 arg1Of Studies,show
R15728 T78691 T18580 arg1Of %,and
R15788 T62294 T79163 arg1Of encephalitis,","
R16551 T73930 T90719 arg2Of day,by
R16578 T20679 T44741 arg2Of COVID19,of
R16749 T10805 T51590 arg1Of ",",and
R16771 T13833 T13700 arg2Of and,","
R16863 T14835 T13628 arg2Of infection,","
R17029 T86080 T42365 arg1Of IgG,and
R17219 T21718 T77014 arg1Of study,decreased
R17542 T6163 T48110 arg1Of improved,","
R1770 T77014 T13833 arg1Of decreased,and
R17888 T21434 T41840 arg1Of possibility,the
R18045 T48684 T8813 arg1Of patients,Most
R1890 T7060 T20581 arg1Of accompany,that
R18986 T65980 T6067 arg1Of saturation,oxygen
R19341 T3471 T26060 arg1Of ratio,PaO2/FIO2
R19665 T32201 T34533 arg1Of treatment,ranging
R19763 T20348 T65200 arg1Of outcome,of
R19944 T43956 T66824 arg1Of as,such
R2046 T90061 T65200 arg2Of patients,of
R20697 T67208 T77083 arg1Of results,in
R20807 T51386 T32237 arg2Of and,against
R20851 T35011 T71611 arg2Of origin,share
R21455 T95212 T84611 arg1Of Hypothesis,:
R22057 T31095 T77014 arg2Of count,decreased
R22109 T23466 T51386 arg1Of NP,and
R22163 T24869 T29802 arg2Of possible,as
R22619 T76795 T90831 arg1Of Nile,West
R22662 T84435 T44273 arg1Of treatment,with
R23224 T62294 T76795 arg1Of encephalitis,Nile
R23512 T67208 T10629 arg2Of results,shown
R23868 T85972 T29990 arg1Of and,that
R24626 T80386 T79863 arg3Of ),(
R24969 T62247 T55724 arg1Of deficiencies,[
R25082 T22631 T6254 arg2Of help,:
R25333 T65830 T56952 arg1Of patients,with
R2548 T53426 T93176 arg1Of RNA,reaches
R2563 T82872 T63033 arg1Of immunoglobulin,20 g/d
R25803 T79772 T47524 arg1Of week,first
R2585 T36179 T74019 arg1Of week,second
R2631 T97802 T80013 arg2Of begin,that
R26320 T95417 T50853 arg1Of IVIG,contains
R26413 T6163 T32422 arg1Of improved,After
R26629 T13833 T79561 arg1Of and,e.g.
R27595 T24866 T7060 arg2Of transition,accompany
R27615 T48129 T64443 arg1Of therapy,accelerate
R27628 T87582 T97802 arg2Of rise,begin
R27976 T73930 T66178 arg1Of day,the
R28181 T27914 T8453 arg2Of administered,be
R28227 T10629 T97483 arg1Of shown,","
R28624 T52785 T92712 arg1Of and,severe
R28808 T44373 T75308 arg2Of have,so
R28995 T9832 T13628 arg1Of sepsis,","
R29116 T51393 T29543 arg1Of detection,in
R29180 T69102 T88119 arg2Of revealed,after
R2970 T25963 T66169 arg1Of corticosteroid,moderate-dose
R29783 T29960 T25638 arg1Of patient,the
R29860 T27007 T55724 arg2Of 21,[
R30216 T55185 T10219 arg2Of avium,","
R30440 T48129 T90120 arg1Of therapy,might
R30475 T65630 T2677 arg2Of tuberculosis,","
R30751 T78997 T69102 arg1Of onset,revealed
R30825 T71868 T54079 arg1Of %,and
R31087 T64515 T30704 arg1Of days,14
R31307 T10629 T44219 arg2Of shown,has
R31347 T98815 T75376 arg1Of COVID-19,demonstrated
R31515 T37666 T30663 arg1Of diseases,that
R31620 T4274 T67075 arg1Of %,94
R31644 T49266 T10805 arg2Of laboratory,","
R31769 T65830 T31198 arg2Of patients,included
R32415 T4274 T73088 arg1Of %,and
R32473 T65630 T67405 arg1Of tuberculosis,Mycobacterium
R32666 T32201 T47689 arg1Of treatment,immunomodulatory
R3294 T31327 T10621 arg2Of 22,[
R33163 T64285 T67888 arg1Of all,of
R33240 T80516 T98862 arg1Of IVIG,improve
R33556 T47949 T53819 arg1Of onset,infection
R33852 T98862 T88012 arg1Of improve,to
R33893 T62247 T68999 arg2Of deficiencies,in
R34056 T48129 T55251 arg1Of therapy,IVIG
R34129 T11859 T80531 arg2Of and,decreased
R34363 T37814 T61939 arg1Of develop,after
R34450 T62247 T52471 arg1Of deficiencies,antibodies
R35046 T64285 T38661 arg1Of all,switching
R35060 T73930 T38757 arg1Of day,14th
R35220 T84785 T86080 arg1Of antibodies,IgG
R35461 T36179 T87676 arg2Of week,during
R35568 T67874 T96660 arg2Of and,show
R35710 T37814 T32237 arg1Of develop,against
R36023 T10219 T2677 arg1Of ",",","
R36109 T85972 T67874 arg1Of and,and
R36176 T52785 T6178 arg1Of and,and
R36223 T24248 T42365 arg2Of IgM,and
R36622 T91618 T27562 arg2Of plus,of
R36752 T84435 T6426 arg1Of treatment,plus
R36970 T25388 T7048 arg1Of course,late
R37061 T95212 T56020 arg1Of Hypothesis,4.2.1
R37373 T51393 T33598 arg1Of detection,against
R37459 T80531 T13833 arg2Of decreased,and
R37840 T13628 T43956 arg2Of ",",as
R38001 T51393 T60810 arg1Of detection,among
R38202 T95152 T64168 arg3Of ],[
R38821 T32201 T26744 arg1Of treatment,currently
R39248 T64443 T89890 arg1Of accelerate,to
R39324 T13833 T58632 arg1Of and,","
R3964 T96672 T78252 arg1Of variety,a
R4003 T6426 T52543 arg2Of plus,following
R40258 T91091 T79089 arg1Of day,the
R40263 T14835 T62406 arg1Of infection,Parvovirus
R40351 T24326 T59786 arg1Of symptoms,worsening
R40508 T65980 T11859 arg2Of saturation,and
R40741 T79772 T35185 arg1Of week,the
R4076 T13833 T83448 arg1Of and,","
R41074 T71868 T4274 arg1Of %,%
R41127 T89545 T54246 arg1Of Studies,show
R41252 T62247 T18422 arg1Of deficiencies,primary
R41260 T60445 T91733 arg1Of immunoglobulin,(
R41521 T64285 T6163 arg1Of all,improved
R41612 T5150 T64443 arg2Of recovery,accelerate
R41659 T50853 T84611 arg2Of contains,:
R41915 T58895 T63732 arg1Of outcomes,paraclinical
R42305 T64615 T46489 arg1Of %,94
R42427 T85015 T87582 arg1Of and,rise
R42816 T93176 T85972 arg1Of reaches,and
R42896 T97867 T41175 arg2Of IVIG,(
R43001 T53426 T40522 arg1Of RNA,decreases
R43963 T58895 T87507 arg1Of outcomes,clinical
R45006 T80516 T69063 arg1Of IVIG,might
R45063 T27914 T10896 arg1Of administered,when
R4510 T91321 T75450 arg1Of help,that
R45347 T97422 T55724 arg3Of ],[
R45642 T22917 T47400 arg2Of dose,to
R45693 T34533 T96539 arg1Of ranging,to
R45922 T32201 T83276 arg1Of treatment,an
R46464 T54707 T29802 arg1Of early,as
R46612 T65830 T55004 arg1Of patients,ten
R46659 T91321 T90120 arg2Of help,might
R46687 T47949 T61939 arg2Of onset,after
R46705 T87507 T10805 arg1Of clinical,","
R46944 T55185 T3443 arg1Of avium,Mycobacterium
R47040 T26688 T69861 arg1Of methylprednisolone,1600 mg/d
R47106 T67776 T67888 arg2Of patients,of
R47112 T87582 T15243 arg1Of rise,from
R47262 T21718 T80531 arg1Of study,decreased
R48496 T85015 T97802 arg1Of and,begin
R48610 T40522 T18711 arg1Of decreases,gradually
R48701 T30704 T43796 arg1Of 14,more
R4871 T84785 T24248 arg1Of antibodies,IgM
R48790 T6178 T68999 arg1Of and,in
R49580 T52785 T43956 arg1Of and,as
R49635 T13833 T52543 arg1Of and,following
R50003 T25963 T65524 arg1Of corticosteroid,short-term
R50369 T21718 T18993 arg1Of study,The
R50386 T89099 T91733 arg3Of ),(
R50799 T27914 T50400 arg1Of administered,so
R50945 T29960 T20464 arg1Of patient,is
R51148 T22631 T69063 arg2Of help,might
R52070 T13628 T15497 arg1Of ",",","
R52555 T7060 T54246 arg2Of accompany,show
R52755 T48373 T85015 arg1Of IgG,and
R52803 T51590 T95692 arg1Of and,","
R53013 T53426 T36950 arg1Of RNA,viral
R53047 T74097 T73088 arg2Of 88,and
R53372 T66875 T44373 arg1Of patients,have
R53482 T2594 T83675 arg1Of peak,its
R53615 T16816 T41175 arg3Of ),(
R53992 T58895 T49266 arg1Of outcomes,laboratory
R5424 T2677 T52785 arg1Of ",",and
R5432 T17705 T6178 arg2Of infections,and
R54321 T42313 T79163 arg2Of HIV,","
R54403 T2182 T41175 arg1Of immunoglobulins,(
R54593 T38563 T93829 arg1Of patients,with
R54860 T91091 T15243 arg2Of day,from
R55232 T86520 T85504 arg1Of immunization,Passive
R55274 T37666 T64366 arg1Of diseases,human
R55554 T8038 T49447 arg1Of infections,difficile
R55634 T83960 T50853 arg2Of pool,contains
R56085 T22917 T88178 arg1Of dose,double
R56679 T79772 T62926 arg2Of week,during
R57386 T93176 T62926 arg1Of reaches,during
R58171 T87582 T54813 arg1Of rise,to
R58487 T30704 T66398 arg1Of 14,or
R58848 T21735 T80547 arg2Of disease,against
R59227 T64443 T91321 arg2Of accelerate,help
R59825 T82872 T91618 arg2Of immunoglobulin,plus
R59827 T32201 T52317 arg2Of treatment,is
R59919 T24326 T75376 arg2Of symptoms,demonstrated
R60224 T71868 T74097 arg1Of %,88
R60239 T48892 T85015 arg2Of IgM,and
R61089 T7048 T81312 arg1Of late,to
R61094 T78997 T33297 arg1Of onset,symptom
R62385 T6595 T61951 arg1Of useful,for
R62745 T38661 T32422 arg2Of switching,After
R63281 T10634 T47481 arg1Of disorders,autoimmune
R63324 T63732 T51590 arg2Of paraclinical,and
R64025 T22917 T27562 arg1Of dose,of
R6445 T24980 T93829 arg2Of COVID19,with
R64474 T76985 T20072 arg1Of Analysis,collected
R64970 T24866 T9522 arg1Of transition,from
R65268 T91348 T96539 arg2Of deficiencies,to
R66734 T98815 T69048 arg1Of COVID-19,who
R67204 T53417 T66297 arg2Of COVID-19,with
R67370 T64615 T78691 arg1Of %,%
R6800 T51386 T55833 arg1Of and,the
R68469 T21434 T32751 arg2Of possibility,poses
R68805 T54707 T25991 arg1Of early,as
R68832 T67776 T16788 arg1Of patients,the
R69581 T22143 T80547 arg1Of protects,against
R6993 T37814 T10621 arg1Of develop,[
R70326 T90061 T66297 arg1Of patients,with
R70781 T2594 T93176 arg2Of peak,reaches
R70932 T80516 T22631 arg1Of IVIG,help
R70976 T25963 T99668 arg1Of corticosteroid,a
R71283 T44373 T90719 arg1Of have,by
R71902 T91321 T21434 arg2Of help,possibility
R72167 T96672 T75647 arg1Of variety,of
R72949 T73739 T6758 arg2Of samples,of
R73123 T53426 T81080 arg1Of RNA,the
R73124 T78691 T87988 arg1Of %,100
R7397 T12037 T52317 arg1Of IVIG,is
R74727 T54079 T29543 arg2Of and,in
R74845 T46489 T18580 arg2Of 94,and
R75502 T10263 T91733 arg2Of 10 g/d,(
R7573 T53426 T78293 arg1Of RNA,of
R7624 T17705 T68317 arg1Of infections,recurrent
R76248 T25388 T44741 arg1Of course,of
R76274 T66430 T64168 arg2Of 23,[
R77199 T20348 T98862 arg2Of outcome,improve
R77337 T10634 T57537 arg2Of disorders,from
R77637 T12179 T10629 arg1Of IVIG,shown
R78212 T25963 T44273 arg2Of corticosteroid,with
R78306 T53799 T10621 arg3Of ],[
R78431 T96672 T61951 arg2Of variety,for
R78894 T72909 T77083 arg2Of case,in
R79029 T31095 T40148 arg1Of count,lymphocyte
R79224 T58895 T27596 arg2Of outcomes,in
R79272 T48431 T27422 arg1Of levels,immunoglobulin
R79540 T60445 T6426 arg2Of immunoglobulin,plus
R79576 T22917 T27854 arg1Of dose,the
R79700 T52785 T60726 arg1Of and,","
R79737 T64515 T20072 arg2Of days,collected
R80044 T2304 T45012 arg1Of antibodies,anti-viral
R80185 T26744 T6595 arg1Of currently,useful
R80380 T52785 T79863 arg2Of and,(
R80609 T65176 T33598 arg2Of NP,against
R80924 T85289 T43666 arg2Of COVID-19,from
R81041 T91091 T92830 arg1Of day,10th
R81045 T18048 T78293 arg2Of 2019-nCoV,of
R81126 T83960 T68527 arg1Of pool,large
R81797 T97267 T51386 arg2Of RBD,and
R82064 T72909 T84121 arg1Of case,of
R82140 T31699 T72940 arg1Of Rationale,4.2.2
R82498 T4187 T38504 arg1Of it,should
R82814 T37666 T75647 arg2Of diseases,of
R82941 T75851 T54040 arg2Of 80 mg/d,(
R82963 T90848 T52785 arg2Of infections,and
R83120 T2182 T55819 arg1Of immunoglobulins,4.2
R84704 T40522 T60597 arg1Of decreases,then
R8504 T67208 T45168 arg1Of results,promising
R85206 T50450 T57480 arg2Of antibodies,of
R85642 T8038 T29310 arg1Of infections,Clostridium
R85646 T51393 T69102 arg2Of detection,revealed
R86188 T2182 T56180 arg1Of immunoglobulins,Intravenous
R86274 T35011 T4369 arg1Of origin,an
R86526 T21718 T31198 arg1Of study,included
R86911 T54246 T44838 arg1Of show,consistently
R87740 T17626 T48238 arg2Of 2019-nCoV,of
R87834 T22143 T4169 arg1Of protects,and
R87985 T83960 T57480 arg1Of pool,of
R8876 T37814 T87676 arg1Of develop,during
R89140 T4169 T15590 arg1Of and,","
R89182 T25963 T54040 arg1Of corticosteroid,(
R89374 T75308 T98992 arg1Of so,that
R89530 T34533 T57537 arg1Of ranging,from
R89732 T3036 T10896 arg2Of diagnosed,when
R89986 T38563 T60810 arg2Of patients,among
R90242 T98862 T22631 arg2Of improve,help
R91107 T91348 T92790 arg1Of deficiencies,antibody
R91116 T20072 T88119 arg1Of collected,after
R91140 T51386 T48238 arg1Of and,of
R91588 T27914 T4169 arg2Of administered,and
R91845 T48684 T37814 arg1Of patients,develop
R92060 T6163 T27596 arg1Of improved,in
R92508 T73098 T54079 arg2Of RBD,and
R92577 T3471 T11859 arg1Of ratio,and
R92669 T12179 T44219 arg1Of IVIG,has
R92905 T31198 T13700 arg1Of included,","
R93295 T6735 T32751 arg1Of It,poses
R9347 T3036 T20464 arg2Of diagnosed,is
R94093 T73739 T88720 arg1Of samples,serum
R94197 T8038 T10219 arg1Of infections,","
R94232 T4187 T27914 arg2Of it,administered
R94505 T48129 T91321 arg1Of therapy,help
R94705 T27914 T38504 arg2Of administered,should
R94792 T91348 T18270 arg1Of deficiencies,primary
R94930 T51393 T49412 arg1Of detection,of
R95215 T35011 T95969 arg1Of origin,idiopathic
R95496 T75851 T15835 arg1Of 80 mg/d,methylprednisolone
R95673 T14835 T99835 arg1Of infection,B19
R95689 T50450 T98962 arg1Of antibodies,human
R96008 T29960 T3036 arg2Of patient,diagnosed
R9661 T98815 T56952 arg2Of COVID-19,with
R96845 T80013 T67874 arg2Of that,and
R96957 T26688 T91618 arg1Of methylprednisolone,plus
R9744 T64615 T69539 arg2Of %,in
R97441 T36179 T56543 arg1Of week,the
R97543 T38661 T47400 arg1Of switching,to
R98284 T76985 T6758 arg1Of Analysis,of
R98402 T27914 T54707 arg1Of administered,early
R98709 T6178 T84121 arg2Of and,of
R99263 T62294 T72325 arg1Of encephalitis,virus
R99309 T52785 T73958 arg1Of and,","
R99315 T40522 T85972 arg2Of decreases,and
R9941 T10629 T23275 arg1Of shown,Also
R99597 T31699 T6254 arg1Of Rationale,:
R99739 T54079 T69539 arg1Of and,in
R99800 T55858 T54040 arg3Of ),(
R9994 T48431 T7060 arg1Of levels,accompany